RedHill Biopharma (RDHL) Interest Expenses (2012 - 2023)

RedHill Biopharma (RDHL) has reported Interest Expenses for 12 consecutive years, with $1.9 million the latest figure, recorded in Q2 2023.

• On a quarterly basis, Interest Expenses fell 54.3% year-over-year to $1.9 million in Q2 2023; TTM through Jun 2023 was $36.6 million, a 131.5% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, down 3.7% from the prior year.
• Interest Expenses was $1.9 million for Q2 2023 at RedHill Biopharma, up from $421000.0 in the prior quarter.
• Over five years, Interest Expenses peaked at $31.8 million in Q3 2022 and troughed at $74000.0 in Q2 2019.
• A 5-year average of $4.2 million and a median of $3.7 million in 2020 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses sank 95.69% in 2019 and jumped 4839.19% in 2020, its largest moves.
• Over 5 years, Interest Expenses stood at $187000.0 in 2019, then surged by 2382.89% to $4.6 million in 2020, then fell by 20.61% to $3.7 million in 2021, then tumbled by 32.69% to $2.5 million in 2022, then retreated by 22.37% to $1.9 million in 2023.
• The last three Interest Expenses figures came in at $1.9 million (Q2 2023), $421000.0 (Q1 2023), and $2.5 million (Q4 2022), per Business Quant data.